Q1 2025 Orion Oyj Earnings Call Transcript
Key Points
- Orion Oyj (ORINY) reported a 15% increase in net sales and a 39% growth in operating profit for Q1 2025.
- All four business divisions, including Innovative Medicines, Branded Products, Generics, and Animal Health, showed growth.
- The company has expanded its R&D capabilities by opening a new site in Cambridge to strengthen pharmaceutical development for biologics.
- The Innovative Medicines division experienced a 70.4% growth, contributing significantly to the company's sales.
- Orion Oyj (ORINY) has a strong clinical pipeline with multiple ongoing Phase III projects, including those for Nubeqa and levosimendan.
- Cash flow decreased due to the timing of royalty and milestone payments.
- Fermion, one of Orion Oyj (ORINY)'s divisions, did not show growth, although it is primarily focused on internal operations.
- There is uncertainty regarding potential US import tariffs, which could impact Orion Oyj (ORINY)'s income, particularly from Nubeqa.
- Operating expenses were lower than anticipated, but there is an expectation of catch-up costs later in the year.
- Generic competition is impacting sales of certain products like Simdax and dex portfolios, leading to a decline.
Good afternoon, ladies and gentlemen, and welcome to Orion's earnings conference call and webcast for the financial period of January, March 2025. My name is Tuukka Hirvonen, I'm the Head of IR here at Orion.
In a few moments, as you know, we will start this event with CEO, Liisa Hurme's presentation. After which, you will have the possibility to ask questions from her and also from our CFO, Mr. René Lindell. We will be first taking questions through the conference call lines, and then you also have the possibility to send in your questions through the webcast question form.
(Operator Instructions) And just before letting Liisa step in, just a reminder about the disclaimer regarding forward-looking statements. And with this, it's my pleasure to hand over to Liisa.
Thank you, Tuukka. And good afternoon on my behalf as well, and welcome to Orion quarter-one 2025 webcast. I'll start with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
